Clearmind Medicine announced the submission of a patent application under the International Patent Cooperation Treaty. This submission is part of the Company’s ongoing collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem, pursuant to the exclusive licensing agreement Clearmind holds with Yissum. The patent application covers innovative compounds invented by Professors Rami Yaka, Ahmed Masaewa, and Avi Priel of the Hebrew University. These novel compounds are designed to treat post-traumatic stress disorder and other mental health conditions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- SciSparc announces publication of international patent application
- Clearmind announces publication of international patent application
- Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
- Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
- SciSparc, Clearmind Medicine deal leads to publication of ketamine combo